Successful treatment of refractory Behçet's disease with the TNF-α blocker infliximab

Iranian Journal of Immunology

Volumn 6, Issue 1, 2009, Pages 55-58

  Jalili, Ahmad ^a   Kinaciyan, Tamar ^a   Barisani, Talin ^b   Peck Radosavljevic, Markus ^b   Stingl, Georg ^a   Geusau, Alexandra ^a   Wöhrl, Stefan ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Behcet's disease; Hepatitis B; Infliximab; TNF alpha

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; PREDNISONE; TENOFOVIR DISOPROXIL; THALIDOMIDE; ADENINE; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; DRUG DERIVATIVE; HLA B ANTIGEN; MONOCLONAL ANTIBODY; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APHTHOUS ULCER; ARTHRALGIA; ARTICLE; BEHCET DISEASE; BRAIN VASCULITIS; CASE REPORT; DRUG MEGADOSE; DRUG TOLERABILITY; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; POLYMERASE CHAIN REACTION; UVEITIS; VIRUS LOAD; VIRUS MUTATION; DRUG ANTAGONISM; GENETICS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADENINE; ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; BEHCET SYNDROME; HEPATITIS B; HLA-B ANTIGENS; HUMANS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 67650376201     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Verity DH, Wallace GR, Vaughan RW, Stanford MR. Behcet's disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003; 87: 1175-83.
2. Evereklioglu C. Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol. 2005; 50: 297-350.
3. Durrani K, Papaliodis GN. The genetics of Adamantiades-Behcet's disease. Semin Ophthalmol. 2008; 23: 73-9.
4. Krause I, Weinberger A. Behcet's disease. Curr Opin Rheumatol. 2008; 20: 82-7.
5. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Clin Exp Dermatol. 2005; 30: 61-3.
6. Ilhan F, Demir T, Turkcuoglu P, Turgut B, Demir N, Godekmerdan A. Th1 polarization of the immune response in uveitis in Behcet's disease. Can J Ophthalmol. 2008; 43: 105-8.
7. Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004; 31: 1362-8.
8. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum. 2005; 52: 2478-84.
9. Asnis GM, De La Garza R 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J Clin Gastroenterol. 2006; 40: 322-35.
10. Harada N, Higuchi K, Yoshiyama T, Kawabe Y, Fujita A, Sasaki Y, et al. Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J Infect. 2008; 56: 348-53.
11. Valesini G, Iannuccelli C, Marocchi E, Pascoli L, Scalzi V, Di Franco M. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev. 2007; 7: 35-41.
12. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol. 1995; 19: 1409-17.
13. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24: 289-93.
14. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 1366-71.